# Study of Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Adult Patients With Allergic Grass Pollen Rhinoconjunctivitis

> **NCT00955825** · PHASE3 · COMPLETED · sponsor: **Stallergenes Greer** · enrollment: 473 (actual)

## Conditions studied

- Allergic Rhinitis Due to Grass Pollens

## Interventions

- **DRUG:** 300 IR
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00955825
- **Lead sponsor:** Stallergenes Greer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 473 (ACTUAL)
- **Last updated:** 2016-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00955825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00955825, "Study of Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Adult Patients With Allergic Grass Pollen Rhinoconjunctivitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00955825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*